Pharmaceutical Products

Detailed Product Description

Safe Estrogen Testolactone CAS 968-93-4 for Breast Cancer

Quick Detail:

Testolactone
Synonyms:13,17-Secoandrosta-1,4-dien-17-oicacid, 13-hydroxy-3-oxo-, d-lactone (6CI,8CI)
D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione
Inchi:InChI=1/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1
CAS No.: 968-93-4
ECNECS No.: 213-534-6
MF: C19H24O3
MW:300.39
Purity : 99%min
Density:1.17g/cm3
Melting Point:218-219 deg C
Boiling Point:482°Cat760mmHg
Refractive Index:1.567
Flash Point:213.4°C
Appearance:White or off-white crystalline powder
Grade : Pharmaceutical Grade
Storage: Shading, confined preservation
Lead time :within 12 hours upon receipt of payment
Delivery: EMS, DHL, TNT, FedEx, UPS

Product description:

Testolactone (brand name Teslac) is an antineoplastic agent that is a derivative of progesterone and is used to treat advanced stage breast cancer.
It is nonselective.
Testolactone is a synthetic antineoplastic agent that is structurally distinct from the androgen steroid nucleus in possessing a six-membered lactone ring in place of the usual five-membered carbocyclic D-ring. Despite some similarity to testosterone, testolactone has no in vivo androgenic effect. No other hormonal effects have been reported in clinical studies in patients receiving testolactone.
The principal action of testolactone is reported to be inhibition of steroid aromatase activity and the reduction in estrone synthesis that follows. Androstenedione, a 19-carbon steroid hormone produced in the adrenal glands and the gonads, is where estrone synthesis originates and is the source of estrogen in postmenopausal women. In vitro studies report that the aromatase inhibition may be noncompetitive and irreversible, and could possibly account for the persistence of this drug& acute;s effect on estrogen synthesis after drug withdrawal.